Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this podcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.
To delve further into the subject matter with added slides and supplementary information, we invite you to explore the video version.
00:55 – Introduction from Prof Beggs “setting the scene”
03:05 – Biopsy types for NGS
07:50 – DNA versus RNA for analysis
13:30 – Processing considerations – an NHS case study
16:20 – Integrating genomic profiling into patient care and management
22:50 – Conclusions
Speaker disclosures
- Grant funding: AstraZeneca Plc, Incyte Inc, MSD, Moderna, Oxford Nanopore, Thermo Scientific, Illumina, BioNano, Innova Medical
- Travel & conference funding: Oxford Nanopore, Thermo Scientific, Illumina, Bayer
- Consultancy: Oxford Nanopore, Check4Cancer, Kiffik Biomedical, 2CureX Ag
- In kind support: MGITech, Illumina, Congenica, Qiagen
- Salary support: MRC Senior Clinical Fellowship
This content is intended only for healthcare providers, excluding UK, and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.
